Efficacy and Safety of Long-Term Tildrakizumab for Plaque Psoriasis: 4-Year Results from Resurface 1 and Resurface 2

Main Article Content

Richard G Langley
Jeffrey Crowley
Melinda Gooderham
Kim A Papp
Neil J Korman
Lynda Spelman
Atsuyuki Igarashi
Mamitaro Ohtsuki
Aditya K Gupta
Paul Yamauchi
Jeffrey Parno
Alan M Mendelsohn
Stephen J Rozzo
Kimberly Eads

Keywords

Psoriasis, Tildrakizumab, Biologics, Safety

Abstract

Abstract not available.

References

1) Reich K, et al. Lancet. 2017;390:276–88;

2) Blauvelt A, et al. Br J Dermatol. 2018;179:615–22.